COMPARISON
Abaloparatide vs Insulin degludec
6 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Abaloparatide is authorised or registered in 5 and Insulin degludec in 10 of the 10 registers read. Abaloparatide: No trial states a phase. Insulin degludec: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Abaloparatide | Insulin degludec | |
|---|---|---|
| Registered trials differs | 25 clinicaltrials.gov · 2026-10-03 | 255 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Tymlos openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Xultophy 100/3.6 openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2022-12-12 ema · 2026-10-03 | 2013-01-20 ema · 2026-10-03 |
| EU refused on differs | 2018-04-03 ema · 2026-10-03 | Not checked no record of "refusedOn" for insulin-degludec |
| ATC code differs | H05AA04 ema · 2026-10-03 | A10AE06 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Abaloparatide | placebo | Insulin degludec | placebo |
|---|---|---|---|---|
| Hypercalciuria | 9.7% | 8.9% | - | - |
| Dizziness | 9.4% | 5.5% | - | - |
| Nasopharyngitis | 8.8% | 8.5% | - | - |
| Arthralgia | 8.3% | 9.3% | - | - |
| Nausea | 8.0% | 3.1% | - | - |
| Headache | 7.2% | 6.1% | - | - |
| Back pain | 7.1% | 8.2% | - | - |
| Upper respiratory tract infection | 6.9% | 7.8% | - | - |
| Hypertension | 6.2% | 6.0% | - | - |
| Influenza | 5.8% | 4.5% | - | - |
Trial register Abaloparatide: 4 placebo-controlled trials; Insulin degludec: 0. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Abaloparatide side effects · Insulin degludec side effects
LEGAL STATUS
Approval in each country read
| Country | Abaloparatide | Insulin degludec | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Not on the register | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.